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action of the flavonoid rutin in an animal model of focal cortical ischemia induced by
unilateral thermocoagulation of superficial blood vessels of motor (M1) and somatosensory
(S1) primary cortices. Ischemic rats were submitted to daily injections (i.p.) for five days,
starting immediately after induction of ischemia. We tested two doses: 50 mg/kg or
100 mg/kg of body weight. Sensorimotor tests were used to evaluate functional recovery.
Bioavailability in plasma was done by chromatographic analysis. The effect of treatment
in lesion volume and neurodegeneration was evaluated 48 h and 72 h after ischemia,
respectively. We observed significant sensorimotor recovery induced by rutin, and the dose
of 50 mg/kg had more pronounced effect. Thus, this dose was used in further analyses.
Plasma availability of rutin was detected from 2 h to at least 8 h after ischemia. The
treatment did not result in reduction of lesion volume but reduced the number of
degenerated neurons at the periphery of the lesion. The results suggest rutin as an
efficient drug to treat brain ischemia since it was able to promote significant recovery of
sensorimotor loss, which was correlated to the reduction of neurodegeneration in the
periphery of cortical injury. Increasing studies with rutin and other flavonoids might give
support for further clinical trials with these drugs.
& 2013 Elsevier B.V. Open access under the Elsevier OA license.39
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Stroke is currently a critical public health problem and a major
cause of death and disability in adults worldwide (Lloyd-Jones
et al., 2009; Lotufo, 2005). Several pathophysiological events aretriggered in brain tissue after an ischemic injury, including
the inflammatory response and oxidative stress damage
(Brouns and De Deyn, 2009; Deb et al., 2010). Thus, drugs with
anti-inflammatory and antioxidative actions have been
expected to have a protective effect in brain ischemia.
b r a i n r e s e a r c h 1 5 0 3 ( 2 0 1 3 ) 5 3 – 6 154Polyphenols are natural substances found in plant products, as
leaves and fruits, oils, wine and tea. They are divided into
phenolic acids, flavonoids and non-flavonoid polyphenols
(Ramassamy, 2006). Like beta-carotene and ascorbic acid, poly-
phenolic compounds are related to protective effects against
cancer and cardiovascular disease (Heim et al., 2002). Flavo-
noids are part of this large group of polyphenolic compounds,
and more than 2000 flavonoids have been identified
(Ramassamy, 2006). The most important pharmacological prop-
erties of flavonoids are its anti-inflammatory and antioxidative
actions (Benavente-Garcı´a and Castillo, 2008; Formica and
Regelson, 1995; Juurlink and Paterson, 1998; Procha´zkova´
et al., 2011). The use of flavonoids has been proposed for
pathologies of central nervous system, such as Parkinson’s
disease, Alzheimer’s disease and stroke, due to such proper-
ties and to data from epidemiological studies (Ramassamy,
2006; Sun et al., 2008).
Rutin, also called as quercetin-3-O-rutinoside, is a flavo-
noid glycoside composed of the flavonoid quercetin and the
disaccharide rutinose that have antioxidative, anti-inflam-
matory, antiallergic, anti-viral and anti-carcinogenic actions
(Arau´jo et al., 2011). Few studies have evaluated the treat-
ment with rutin in models of global and focal brain ischemia,
showing positive effects (Gupta et al., 2003; Khan et al., 2009).
Rutin administration has been evaluated in a model of focal
brain ischemia, revealing protective action (Khan et al., 2009).
However, only pre-ischemic administration was assessed
(Khan et al., 2009).
Here, we studied the effect of treatment with rutin after
induction of focal cortical ischemia. Thus, we aimed to
analyze whether this flavonoid could be used as medicine
to treat brain ischemia. We applied rutin into the acute phaseFig. 1 – Recovery of the impaired forelimb in the cylinder test.
control (n¼7), R50 (n¼6) and R100 (n¼7) groups before ischemi
asymmetry was observed at PID 2. R50 group was significantly d
91, showing a higher level of recovery. R100 group showed reco
between control and R50 groups, # represents the comparison
comparison between R50 and R100 groups. (n or U¼po0.05; ##of ischemia and evaluated its bioavailability and its effects on
sensorimotor recovery and neurodegeneration.2. Results
2.1. Behavioral analyses
To evaluate whether the administration of rutin after induc-
tion of cortical ischemia results in any functional recovery,
ischemic animals were treated with rutin and their sensor-
imotor performance was measured.
In cylinder test, statistical analysis showed significant
‘‘treatment x day’’ interaction (F¼1.56, po0.05) and signifi-
cant effects of treatment (F¼3.61, po0.05) and day (F¼16.5,
po0.0001). Comparisons among groups showed more marked
recovery in R50 group, and R100 showed discrete effect
(Fig. 1). Thus, rutin promoted significant recovery of contral-
ateral forelimb performance in support during vertical
exploration. Similarly, in adhesive test, statistical analysis
showed significant ‘‘treatment x day’’ interaction (F¼1.64,
po0.05) and significant effects of treatment (F¼5.18, po0.05)
and day (F¼30.19, po0.0001). Comparisons among groups
also showed more marked recovery in R50 group than in R100
group (Fig. 2). Sham animals were also evaluated and showed
no significant lost of function (Fig. 2). Thus, rutin promoted
significant recovery of adhesive removal with contralateral
forelimb after tactile stimulation.
Together, these results suggest that post-ischemic
treatment with rutin is effective to recover sensorimotor
function after cortical focal ischemia. Since the dose ofGraph showing the accompaniment of the performance of
a and along post-ischemic weeks. In all groups, the greater
ifferent from the control group at PIDs 14, 28, 49, 70, 84 and
very only at PIDs 70 and 84. n represents the comparison
between control and R100 groups and U represents the
¼po0.01; nnn¼po0.001; Tukey).
Fig. 2 – Recovery of the impaired forelimb in the adhesive test. Graph showing the accompaniment of the performance of
control (n¼11), R50 (n¼10) and R100 (n¼10) groups before ischemia and along post-ischemic weeks. Sham group (n¼5) was
accompanied until PID 42 and was shown to illustrate the lack of impairment. This group was not considered in statistical
analysis. In all groups, the lower level of contralateral preference was observed at PID 2. R50 group was significantly different
from the control group at PIDs 14, 21, 28, 35, 42, 56 and 77, showing a higher level of recovery. R100 group showed recovery at
PIDs 56, 70, 77 and 91. Points in the graph represent mean7SEM. n represents the comparison between control and R50
groups, # represents the comparison between control and R100 groups and U represents the comparison between R50 and
R100 groups (n or #¼po0.05; ## or UU¼po0.01; nnn¼po0.001; Tukey).
Table 1 – Values found for each animal in HPCL
experiment.
Time (h) Plasmatic concentration
of rutin (mg/ml)
Mean7SD
2 0.87 0.9370.54
1.50
0.42
4 1.28 0.9970.31
1.02
0.67
6 0.62 0.6070.07
0.52
0.65
8 0.79 0.4570.31
0.37
0.19
b r a i n r e s e a r c h 1 5 0 3 ( 2 0 1 3 ) 5 3 – 6 1 5550 mg/kg showed better result, it was used in further
experiments.
2.2. Detection of rutin in plasma
Experiments with HPLC showed the presence of rutin in
plasma from 2 h to atleast 8 h after i.p. injection, with a peak
at 2–4 h (Table 1, Fig. 3). Two equations showed a close fit for
obtained data, and both statistic comparisons with F test
(equation (1) as the null hypothesis, F¼0.09, p¼0.77) and
Alkaike’s Information Criteria (AlCc) (% equation (1)/% equa-
tion (2)¼17.24) indicated equation (1) (two phase exponential
association) as the preferred model (Table 2, Fig. 3).
2.3. Lesion volume
As previously shown (Giraldi-Guimar ~aes et al., 2009; Szele
et al., 1995), the procedure of thermocoagulation induced a
consistent ischemic lesion that included the six cortical
layers, sparing the white matter as revealed by reaction with
TTC (Fig. 4). Sham procedure induced no recognizable lesion
(Fig. 4). Treatment with rutin promoted no significant reduc-
tion of ischemic lesion volume (p¼0.65, Figs. 4 and 5).
2.4. FJC staining
As previously shown (Giraldi-Guimar ~aes et al., 2009), the
procedure of thermocoagulation induced large neurodegen-
eration, as revealed by FJC staining. The majority of FJCþ cellswere observed in the core of the lesion (not shown), but a
significant number of stained cells was also observed in the
periphery of the lesion (Fig. 6). The number of FJCþ cells
observed in the periphery of the lesion was higher in animals
of the control group than in those of R50 group (Fig. 6).
Quantification revealed that this difference was statistically
significant (Fig. 7).3. Discussion
In recent years, research on flavonoids is increasing. The
interest in these compounds is due to the evidence of various
Fig. 3 – Plasmatic concentration of rutin. Graph showing the time course of plasmatic concentration of rutin after i.p.
administration with a dose of 50 mg/kg. The measured times were 2, 4, 6 and 8 h (for each time, n¼3). Time 0 h was plotted
as 0 for regression analysis. Solid line represents the fit of nonlinear regression with equation (1), and dashed line represents
the fit with equation (2) (see Table 2). Points in the graph represent mean7SEM.
Table 2 – Equations of nonlinear regression.
Two phase exponential association.
Y¼Ymax1 (1exp(–K1X))þYmax2 (1exp(–K2X)) (1)
Best-fit values
Ymax1 3.489
K1 0.06417
Ymax2 1.839
K2 0.6874
Two phase exponential decay.
Y¼Span1exp(K1X)þSpan2 exp(K2X)þplateau (2)
Best-fit values
Span1 5.659
K1 0.2680
Span2 5.573
K2 0.4495
Plateau 0.08949
b r a i n r e s e a r c h 1 5 0 3 ( 2 0 1 3 ) 5 3 – 6 156pharmacological properties and their presence in many human
foods (Muzitano et al., 2008; Dajas et al., 2003). Furthermore,
epidemiological studies have evaluated the correlation between
reduced rates of cardiovascular disease and cytoprotection in
neurological disorders in populations with diets rich in flavo-
noids (Bastianetto and Quirion, 2002 Esposito et al., 2002;
Procha´zkova´ et al., 2011). In fact, recent studies with flavonoids
in models of brain ischemia, most of them with the flavonoid
widely found in plant products, quercetin, have shown signifi-
cant neuroprotection and promotion of functional outcome
(Lee et al., 2011; Rivera et al., 2008).
A flavonoid with molecular structure similar to quercetin
and putative neuroprotective action is rutin. Few previous
studies with models of global brain ischemia have been con-
ducted, showing protective effect of rutin when administrated
in pre-ischemic stage (Abd-El-Fattah et al., 2010; Gupta et al.,
2003; Pu et al., 2007) or after ischemia induction (Gupta et al.,
2003). Regarding focal ischemia, a recent study evaluated rutin
administration during 21 days before the induction of ischemiabymiddle cerebral artery occlusion (MCAO), revealing protective
action (Khan et al., 2009). Here, we studied the therapeutic
potential of rutin when administrated after induction of focal
thermocoagulatory ischemic lesion in sensorimotor cortex, a
model previously used by our research group to investigate
therapeutic approaches (Giraldi-Guimar ~aes et al., 2009). Admin-
istration of rutin from the beginning of ischemic process, by
daily i.p. injections during the first five post-ischemic days,
promoted sensorimotor recovery of impaired forelimb. More-
over, although no reduction of lesion volume was found, rutin
reduced neurodegeneration in lesion periphery. Thus, the
results indicate that rutin also has significant neuroprotective
effect when administrated after the occurrence of a focal
cortical ischemia, suggesting that this flavonoid might be used
to treat ischemic damage in the acute phase of stroke.
We observed more sensorimotor recovery with the dose of
50 mg/kg than with 100 mg/kg. We are not able to explain this
result, but previous reports about treatment of focal brain
ischemia with quercetin, a structurally related flavonoid,
have also shown better effects with lower than with higher
doses (Pandey et al., 2011; Rivera et al., 2004). After post-
mortem observation of the peritoneal cavity of our animals,
we observed that those treated with 100 mg/kg had clusters
of insoluble rutin, which was not observed in those treated
with 50 mg/kg (data not shown). Some reasons for the
instability of rutin solution in the peritoneal cavity are its
aqueous environment and its range of pH values (7.46–8.10)
(Noh, 2003), which turns flavonols less soluble in water when
compared to neutral and acidic conditions. These peritoneal
cavity features could lead to a precipitation of rutin when it is
in higher concentrations, which might have some negative
influence on the absorption by the blood vessels of the
peritoneal membrane (e.g., reduction of membrane surface
for absorption of the soluble rutin and inhibition by satura-
tion of receptors involved in the absorption). Moreover,
further toxicological studies about the possible deleterious
effect of high doses of flavonoid are needed to help explain
the better results of lower doses.
Fig. 4 – Extension of the ischemic lesion induced by thermocoagulation. Sequential images of coronal brain slices of a sham
animal (representative of four sham animals), a control animal (representative of four control animals) and a R50 animal
(representative of four R50 animals). All sections were reacted with TTC 48 h after surgery. From top to bottom, the images of
each animal were placed in order from most rostral portion to most caudal portion of the ischemic lesion. In sham animals,
the same regions were analyzed, but no lesion was observed. Each line represents the same stereotaxic region, and these
five regions were standardized for lesion volume quantification.
Fig. 5 – Evaluation of ischemic lesion volume. The dose of
50 mg/kg of rutin promoted no significant reduction in
ischemic lesion volume. Control group, n¼4; R50 group,
n¼4. Bars in the graph represent meanþSEM.
b r a i n r e s e a r c h 1 5 0 3 ( 2 0 1 3 ) 5 3 – 6 1 57Similar to other flavonoids, the main expected mechan-
isms of action of rutin are its anti-inflammatory and anti-
oxidative potential. In fact, anti-inflammatory action of rutin
was demonstrated with reduction of inducible nitric oxide
synthase expression in a model of Parkinson’s disease (Khan
et al., 2012). Neuroprotective effect of rutin was also corre-
lated to its action as an antioxidant. Rutin has been described
as a scavenger of superoxide radicals, which is highly formed
during ischemic process (Khan et al., 2009). Pretreatment
with rutin resulted in attenuation of the elevated levels of
thiobarbituric acid reactive species, hydrogen peroxide and
protein carbonyl induced by ischemia (Gupta et al., 2003;
Khan et al., 2009). Moreover, its action also includes protec-
tion of biological antioxidative systems. Pretreatment with
rutin resulted in protection against inhibition of antioxidant
enzymes activity after MCAO (Khan et al., 2009). Indeed,
beside these neuroprotective actions on already established
ischemic injury, the therapeutic potential of rutin should be
still higher. Rutin was recently found to be an inhibitor of
Fig. 6 – Evaluation of neurodegeneration after ischemia by FJC staining. Images of the three portions (lateral, ventral and
medial) of the lesion periphery that were analyzed, taken from representative coronal sections of control and R50 animals.
Note that the number of FJCþ (degenerating) neurons was greater in control than in R50 animals.
Fig. 7 – Quantification of degenerating neurons. The dose of
50 mg/kg of rutin promoted significant reduction in the
number of FJCþ neurons in the lesion periphery. Control
group, n¼4; R50 group, n¼4. Bars in the graph represent
meanþSEM. n¼po0.05.
b r a i n r e s e a r c h 1 5 0 3 ( 2 0 1 3 ) 5 3 – 6 158protein disulfide isomerase and this action potently
blocks thrombus formation in mice, pointing to rutin as a
preventive approach for cardiac ischemia and stroke (Jasuja
et al., 2012).
In conclusion, the study contributes to suggest the flavo-
noid rutin as a putative candidate to treat stroke. Beside
previous descriptions of the efficacy of pre-treatment in
models of brain ischemia, the results suggest that its neuro-
protective effect is also relevant to be used after the occur-
rence of stroke, in the acute phase of the disease. Thus,
flavonoids might be suggested as another option in the
arsenal of possible therapeutic approaches to treat stroke.Increasing studies about neuroprotective action of flavonoids
in animal models of brain ischemia might support, soon,
further clinical trials with this class of drugs.4. Experimental procedures
4.1. Animals
The experiments were carried out in accordance with the
National Institute of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Animal Ethics
Committee of our institution. Male Wistar rats which were
2–3 months of age at the beginning of the experiment were
used. All animals were housed in a colony room with
controlled temperature, and with food and water available
ad libitum. Before experimental procedures, animals were
submitted to handling for five consecutive days to adapt to
the experimenter and minimize stress.
4.2. Surgery
Thermocoagulation of the blood in the submeningeal blood
vessels of the motor and sensorimotor cortices was used to
induce ischemic lesion as previously described (Giraldi-
Guimar ~aes et al., 2009; Szele et al., 1995). Briefly, animals
were anesthetized with ketamine hydrochloride (90 mg/kg)
and xylazine hydrochloride (10 mg/kg) and placed in a
stereotaxic apparatus (Insight Ltda., Ribeir ~ao Preto, SP, Brazil).
Skull was exposed, and a craniotomy was performed, expos-
ing the frontoparietal cortex contralateral to the preferred
forelimb in the adhesive test (see Section 2.4.) (þ2 to 6 mm
A.P. from bregma; according to the atlas of Paxinos and
Watson (2005). Blood was thermocoagulated transdurally by
approximation of a hot probe to the dura mater. Sham
b r a i n r e s e a r c h 1 5 0 3 ( 2 0 1 3 ) 5 3 – 6 1 59operated animals suffered only the craniotomy. After proce-
dure, skin was sutured, and animals were kept warm under a
hot lamp and returned to colony room after recovery from
anesthesia.
4.3. Rutin administration
The flavonoid rutin was purchased commercially (Sigma-
Aldrich, St. Louis, MO, USA). Rutin was diluted in propylene
glycol. To facilitate the dissolution of rutin, the solution was
made to stand for 15 min in a water bath at 50 1C for 10 min.
Rutin solution or vehicle (propylene glycol) was administered
by intraperitoneal (i.p.) injection. Ischemic animals were
divided into three experimental groups: one that received
vehicle (control group), one that received the dose of 50 mg of
rutin/kg of body weight (R50 group) and one that received the
dose of 100mg/kg (R100 group). These doses were chosen from
previous studies showing protective effect of rutin in models of
global brain ischemia (Abd-El-Fattah et al., 2010; Pu et al., 2007).
For behavioral analyses, all groups were used and the protocol
of treatment was a daily injection during five consecutive days,
starting just after the end of surgical procedure. In other
analyses, as explained below, control and R50 groups were
used with changes in protocol of treatment.
4.4. Behavioral tests
Functional recovery of the forelimb contralateral to the
ischemic cortical hemisphere was evaluated using two sen-
sorimotor tests: cylinder test and adhesive test (Schallert,
2006). Their effectiveness to assess sensorimotor function
has been shown after thermocoagulatory cortical lesion (de
Vasconcelos dos Santos et al., 2010, Giraldi-Guimar ~aes et al.,
2009). All animals were tested one day before ischemia and at
post-ischemic day (PID) 2, and then weekly. Pre-ischemic day
was plotted in graphs as PID 0. Tests were performed as
previously described (de Vasconcelos dos Santos et al., 2010,
Giraldi-Guimar ~aes et al., 2009). Briefly, in the forelimb use
asymmetry (cylinder) test, a trial consisted in placing the
animal inside a glass cylinder (20 cm diameter X 30 cm
height). Supports in the wall with ipsilateral (to the lesion)
forelimb, contralateral forelimb or simultaneous support
with both forelimbs were counted during vertical exploration.
For each animal at each PID, percentage relative to the total
number of uses (ipsilateralþcontralateralþsimultaneous) was
calculated for ipsilateral (unimpaired) and contralateral
(impaired) uses. An asymmetry score for each animal was
calculated at each PID by the following formula: asymmetry
score¼ (% of ipsilateral uses)(% of contralateral uses). Animals
with asymmetry score higher than 15 at PID 0 were discarded
for statistical analysis.
In the adhesive removal patch test, a small round adhesive
paper (13 mm diameter) was placed on the inner portion of
each wrist of the animal. One trial consisted in placing the
adhesive papers and their subsequent removal by the animal.
Four trials were applied at each PID, and trials were always
separated by at least 5 min. Preference was evaluated, and in
each trial the first side (ipsilateral or contralateral to the
lesion) of removal was recorded. For each animal at each PID,
percentage of contralateral preference relative to the totalnumber of removals (four) was calculated. Animals with
preference to the right forelimb (more than 50% of first
removal at pre-ischemic day) suffered focal ischemia in the
left hemisphere (see Section 2.2.), and vice-versa. To check for
lack of influence of whole experimental procedure in func-
tional loss, untreated sham animals were also evaluated in
adhesive test.
4.5. Detection of rutin in plasma by high performance
liquid chromatography (HPLC) coupled with a diode array
detector
To evaluate the plasmatic absorption of rutin after an i.p.
injection, animals from R50 group were euthanized with CO2
2, 4, 6 or 8 h after the injection. Animals from the control
group were also evaluated. Blood was collected by cardiac
puncture with heparin and the plasma obtained by centrifu-
gation at 12,000 g for 10 min. Plasma was acidified to pH 4.0
with phosphoric acid. After acidification, methanol was
added (1000 ml: 200 ml of plasma), and the sample was stirred
for 1 min and centrifuged at 12,000 g for 10 min. Supernatant
was collected, and the organic solvent was evaporated. Pellet
was reconstituted with 200 ml of acidified water and analyzed
using HPLC (LC-100, Shimadzus) with reverse-phase column
(RP-18, 5 mm, 4.0250 mm2, Mercks), detector (SPD-M20A,
prominence diode array detector, Shimadzus), loop injection
of 20 mL, pump (LC 20 AT, prominence liquid chromatograph,
Shimadzus), injector (Rheodyne 7725i) and software LC
Solution. The eluents were purified water adjusted to pH 3.2
with formic acid (A) and acetonitrile (B). The following
solvent gradient was applied: from 100% A and 0% B to 80%
A and 20% B within 10 min; from 80% A and 20% B to 75% A
and 25% B within 5 min; from 75% A and 25% B to 70% A and
30% B within 10 min; from 70% A and 30% B to 50% A and 50%
B within 10 min; and from 50% A and 50% B to 0% A and 100%
B within 15 min (total analysis time: 45 min). Flow elution
was 1 mL min1; 20 mL of plasma samples were injected.
UV–vis spectra were recorded in the range 210–350 nm.
The flavonoid quantification was carried out using cali-
bration graph with nine data points. Calibration graph for
HPLC was recorded with rutin amounts ranging from 0.156 to
50.0 mg/mL. The relationship between peak areas (detector
responses) and amount of rutin was linear (r2¼0.9953). To
evaluate the repeatability of the injection integration, the
rutin standard solution and all samples were injected three
times and the relative standard deviation values were calcu-
lated. Identification was performed comparing the retention
time (tR) and UV spectrum of peaks in the samples of plasma
with standard rutin: tR¼18.6 min (97.5% purity).
4.6. Quantification of lesion volume
To quantify the extension of lesion, animals from control and
R50 groups suffered two injections, one just after the end of
surgical procedure and other 24 h after ischemia. They were
euthanized with CO2 48 h after ischemia. Untreated sham
animals were also evaluated to check for lack of cortical
injury. Brains were rapidly removed from the skull and
sectioned in the coronal plane at 2 mm thickness using a
rat brain blocker/slicer (Insight Ltda.). The slices (five for each
b r a i n r e s e a r c h 1 5 0 3 ( 2 0 1 3 ) 5 3 – 6 160animal) were immersed for 30 min into 2% 2,3,5-triphenyl
tetrazolium chloride (TTC) solution at 37 1C. Digital images
from reacted slices were captured under conventional light
illumination using a Nikon digital camera (Nikon Co., Tokyo,
Japan) coupled to a dissecting microscope and a PC computer.
Lesion areas of slices were measured from digital images
using the ImageJ software (NIH). The lesion area of each slice
was multiplied by its thickness (2 mm), obtaining the volume
(mm3). For each animal, the total lesion volume was calcu-
lated by summing the lesion volumes of its slices.
4.7. Fluoro-Jade C (FJC) staining
To analyze the effect of treatment with rutin in neurodegen-
eration, animals from control and R50 groups suffered three
injections, one just after the end of surgical procedure, one
24 h and one 48 h after ischemia. They were euthanized with
CO2 72 h after ischemia and intracardially perfused with cold
0.9% NaCl solution followed by a solution of 4% paraformal-
dehyde, in 100 mM phosphate buffer (pH 7.4). Brains were
removed and immersed in 100 mM phosphate buffer contain-
ing 20% sucrose for 24 h at 10 1C. Brains were sectioned in the
coronal plane at 30 mm thickness at 20 1C on a CM 1850
cryostat (Leica Instruments GmbH, Heidelberg, Baden-Wurt-
temberg, Germany). Sections were subjected to FJC staining,
in accordance with the manufacturer’s instructions (Schmued
et al., 2005). Briefly, they were immersed in a solution of 1%
sodium hydroxide in 80% alcohol for 5 min, 70% alcohol for
2 min, distilled water for 2 min, and 0.06% potassium per-
manganate for 15 min. They were immersed into a solution
of 0.0005% FJC (Histo-Chem Inc., Jefferson, AR, USA) in 0.1%
acetic acid vehicle for staining for 30 min, rinsed three times
in distilled water and allowed to dry at 45 1C for 20 min before
mounting with DPX medium (Electron Microscopy Sciences,
Hatfield, PA, USA).
FJC-positive (FJCþ) cell counting was done as previously
described (Giraldi-Guimar ~aes et al., 2009), but with some
changes. Six sections located inside the rostro-caudal exten-
sion of the lesion were selected per animal. Stereotaxic
positions of the selected sections were standardized for all
animals. Cortical tissue surrounding the ischemic lesion was
considered the periphery of the lesion, and only this region
was considered for quantification. At coronal plane, cortical
ischemic lesion has three well defined regions: lateral, ventral
and medial. For each section, a digital image was captured
from lesion periphery in each lesion region. Images were
taken under fluorescent illumination (fluorescein filter) using
a Zeiss AxioCam digital camera coupled to an Axioplan
microscope (Carl Zeiss Inc., Germany) and a PC computer
with Zeiss Axiovision 4.8 Software. FJCþ cells were counted
from each image (18 images per animal), and the area where
cells were included was measured using the ImageJ software.
The final value for each animal was S (cells counted per
image)/S (area containing labeled cells per image, in mm2).
4.8. Statistical analyses
Nonlinear regression was done with the HPLC data. F test and
AlCc were used to compare and find the best curve fit
(Table 2). Unpaired t test was performed for comparisonamong groups in lesion volume and FJCþ cell counting
analyses. For behavioral analyses, repeated measures two-
way ANOVA (‘‘treatment’’ ‘‘PID’’; PID as the matched factor)
was used, followed by Tukey multiple comparisons post test.
The level of significance was set at po0.05.Acknowledgments
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